睿知中国医院研究地图
候选清单

即将招募肺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

ClinicalTrials.gov 上登记的一项肺癌开放试验,由湖南省肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方湖南省肿瘤医院Hunan Cancer Hospital长沙医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07001995,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) with a sensitizing EGFR mutation (exon 19 deletion or L858R, with or without concurrent mutations).

    入选标准第 4 条

    Prior treatment with EGFR-TKI, with documented disease progression and histologically confirmed small-cell lung cancer (SCLC) transformation.

    入选标准第 5 条

  3. Pregnancy (confirmed by serum ß-hCG) or breastfeeding. Note: Women who have been postmenopausal for ≥ 12 months, or who have undergone hysterectomy, bilateral oophorectomy, or bilateral tubal ligation, are exempt from contraception requirements. Male participants must use effective contraception from the first dose of study drug until 180 days after the last dose.

    排除标准第 6 条

  4. ECOG performance status 0-1 (see Appendix for ECOG scale).

    入选标准第 7 条

  5. ANC ≥ 1,500/mm³

    入选标准第 10 条

    Hemoglobin ≥ 9 g/dL

    入选标准第 11 条

    Platelets ≥ 90,000/mm³

    入选标准第 12 条

    Total bilirubin ≤ 1.5 × ULN

    入选标准第 14 条

    AST and ALT ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with known hepatic metastases)

    入选标准第 15 条

    Serum creatinine within normal limits OR creatinine clearance ≥ 50 mL/min (Cockcroft-Gault)

    入选标准第 17 条

    For patients with BMI < 18.5 or > 30, eGFR ≥ 50 mL/min (MDRD) is acceptable

    入选标准第 18 条

  6. At least one measurable target lesion per RECIST v1.1.

    入选标准第 6 条

  7. Histology at initial diagnosis of small-cell lung cancer (SCLC), large-cell carcinoma, or mixed tumor with predominant SCLC, large-cell, or neuroendocrine components.

    排除标准第 2 条

    Any concurrent malignancy other than basal cell carcinoma of the skin or carcinoma in situ of the cervix. (Patients with a prior malignancy must be disease-free for ≥ 5 years to be eligible.)

    排除标准第 5 条

    Active hepatitis B (HBV DNA > 1,000 IU/mL) or hepatitis C infection (anti-HCV positive and/or HCV RNA > 15 IU/L), or known HIV infection.

    排除标准第 7 条

  8. Women planning pregnancy during the screening period or who, along with their partners, are not using effective contraception.

    排除标准第 10 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07001995,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patients must meet all of the following to be eligible for enrollment:
  2. Signed written informed consent prior to any study-related procedures.
  3. Age ≥ 18 and ≤ 80 years.
  4. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) with a sensitizing EGFR mutation (exon 19 deletion or L858R, with or without concurrent mutations).
  5. Prior treatment with EGFR-TKI, with documented disease progression and histologically confirmed small-cell lung cancer (SCLC) transformation.
  6. At least one measurable target lesion per RECIST v1.1.
  7. ECOG performance status 0-1 (see Appendix for ECOG scale).
  8. Estimated life expectancy > 3 months.
  9. Adequate bone marrow function, defined as:
  10. ANC ≥ 1,500/mm³
  11. Hemoglobin ≥ 9 g/dL
  12. Platelets ≥ 90,000/mm³
  13. Adequate hepatic function, defined as:
  14. Total bilirubin ≤ 1.5 × ULN
  15. AST and ALT ≤ 2.5 × ULN (or ≤ 5 × ULN in patients with known hepatic metastases)
  16. Adequate renal function, defined as:
  17. Serum creatinine within normal limits OR creatinine clearance ≥ 50 mL/min (Cockcroft-Gault)
  18. For patients with BMI < 18.5 or > 30, eGFR ≥ 50 mL/min (MDRD) is acceptable
  19. Adequate cardiac function, defined as LVEF ≥ 50% by MUGA scan or echocardiography.
  20. Women of childbearing potential and men with partners of childbearing potential must agree to use effective contraception.

排除标准:Exclusion Criteria:

  1. Patients meeting any of the following criteria will be excluded from the study:
  2. Histology at initial diagnosis of small-cell lung cancer (SCLC), large-cell carcinoma, or mixed tumor with predominant SCLC, large-cell, or neuroendocrine components.
  3. Prior treatment with a standard SCLC chemotherapy regimen (e.g., carboplatin/etoposide or cisplatin/etoposide) after SCLC transformation.
  4. Symptomatic or unstable brain metastases. Patients with a history of unstable brain metastases must have undergone definitive surgery or radiotherapy, remain clinically stable, and be off corticosteroids for cerebral edema for at least 14 days before enrollment.
  5. Any concurrent malignancy other than basal cell carcinoma of the skin or carcinoma in situ of the cervix. (Patients with a prior malignancy must be disease-free for ≥ 5 years to be eligible.)
  6. Pregnancy (confirmed by serum ß-hCG) or breastfeeding. Note: Women who have been postmenopausal for ≥ 12 months, or who have undergone hysterectomy, bilateral oophorectomy, or bilateral tubal ligation, are exempt from contraception requirements. Male participants must use effective contraception from the first dose of study drug until 180 days after the last dose.
  7. Active hepatitis B (HBV DNA > 1,000 IU/mL) or hepatitis C infection (anti-HCV positive and/or HCV RNA > 15 IU/L), or known HIV infection.
  8. Known hypersensitivity to lietinib, carboplatin, or etoposide.
  9. Psychiatric or cognitive disorders that would preclude informed consent or compliance with study requirements.
  10. Women planning pregnancy during the screening period or who, along with their partners, are not using effective contraception.
  11. Any other medical or psychosocial condition judged by the investigator to compromise patient safety or study integrity (e.g., poor compliance or comorbidities affecting efficacy assessment).

引自 ClinicalTrials.gov, NCT07001995, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07001995,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07001995